CBAY
Cymabay Therapeutics
CBAY
CBAY
Delisted
CBAY was delisted on the 21st of March, 2024.
139 hedge funds and large institutions have $775M invested in Cymabay Therapeutics in 2023 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 43 increasing their positions, 37 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
139
Holders Change
+21
Holders Change %
+17.8%
% of All Funds
2.22%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.16%
New
42
Increased
43
Reduced
37
Closed
20
Calls
$6.51M
Puts
$3.42M
Net Calls
+$3.09M
Net Calls Change
+$1.8M
Top Buyers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$54.5M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$34M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$27.9M |
| 4 |
PA
Perceptive Advisors
New York
|
+$27.9M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
+$23.6M |
Top Sellers
| 1 |
CC
Commodore Capital
New York
|
-$32.4M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$24.9M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$13.6M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$9.09M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$9.02M |
